Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 study
We evaluated the feasibility of ruxolitinib therapy followed by a reduced-intensity conditioning (RIC) regimen for patients with myelofibrosis (MF) undergoing transplantation in a 2-stage Simon phase II trial. The aims were to decrease the incidence of graft failure (GF) and nonrelapse mortality (NR...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2018
|
| _version_ | 1797059137724481536 |
|---|---|
| author | Gupta, V Kosiorek, H Mead, A Klisovic, R Galvin, J Berenzon, D Yacoub, A Viswabandya, A Mesa, R Goldberg, J Price, L Salama, M Weinberg, R Rampal, R Farnoud, N Dueck, A Mascarenhas, J Hoffman, R |
| author_facet | Gupta, V Kosiorek, H Mead, A Klisovic, R Galvin, J Berenzon, D Yacoub, A Viswabandya, A Mesa, R Goldberg, J Price, L Salama, M Weinberg, R Rampal, R Farnoud, N Dueck, A Mascarenhas, J Hoffman, R |
| author_sort | Gupta, V |
| collection | OXFORD |
| description | We evaluated the feasibility of ruxolitinib therapy followed by a reduced-intensity conditioning (RIC) regimen for patients with myelofibrosis (MF) undergoing transplantation in a 2-stage Simon phase II trial. The aims were to decrease the incidence of graft failure (GF) and nonrelapse mortality (NRM) compared with data from the previous Myeloproliferative Disorders Research Consortium 101 Study. The plan was to enroll 11 patients each in related donor (RD) and unrelated donor (URD) arms, with trial termination if ≥3 failures (GF or death by day +100 post-transplant) occurred in the RD arm or ≥6 failures occurred in the URD. A total of 21 patients were enrolled, including 7 in the RD arm and 14 in the URD arm. The RD arm did not meet the predetermined criteria for proceeding to stage II. Although the URD arm met the criteria for stage II, the study was terminated owing to poor accrual and a significant number of failures. In all 19 transplant recipients, ruxolitinib was tapered successfully without significant side effects, and 9 patients (47%) had a significant decrease in symptom burden. The cumulative incidences of GF, NRM, acute graft-versus-host disease (GVHD), and chronic GVHD at 24 months were 16%, 28%, 64%, and 76%, respectively. On an intention-to-treat basis, the 2-year overall survival was 61% for the RD arm and 70% for the URD arm. Ruxolitinib can be integrated as pretransplantation treatment for patients with MF, and a tapering strategy before transplantation is safe, allowing patients to commence conditioning therapy with a reduced symptom burden. However, GF and NRM remain significant. |
| first_indexed | 2024-03-06T19:59:57Z |
| format | Journal article |
| id | oxford-uuid:26ecabe7-b780-45db-979d-fd1adb58b3ad |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:59:57Z |
| publishDate | 2018 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:26ecabe7-b780-45db-979d-fd1adb58b3ad2022-03-26T12:03:59ZRuxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 studyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:26ecabe7-b780-45db-979d-fd1adb58b3adEnglishSymplectic Elements at OxfordElsevier2018Gupta, VKosiorek, HMead, AKlisovic, RGalvin, JBerenzon, DYacoub, AViswabandya, AMesa, RGoldberg, JPrice, LSalama, MWeinberg, RRampal, RFarnoud, NDueck, AMascarenhas, JHoffman, RWe evaluated the feasibility of ruxolitinib therapy followed by a reduced-intensity conditioning (RIC) regimen for patients with myelofibrosis (MF) undergoing transplantation in a 2-stage Simon phase II trial. The aims were to decrease the incidence of graft failure (GF) and nonrelapse mortality (NRM) compared with data from the previous Myeloproliferative Disorders Research Consortium 101 Study. The plan was to enroll 11 patients each in related donor (RD) and unrelated donor (URD) arms, with trial termination if ≥3 failures (GF or death by day +100 post-transplant) occurred in the RD arm or ≥6 failures occurred in the URD. A total of 21 patients were enrolled, including 7 in the RD arm and 14 in the URD arm. The RD arm did not meet the predetermined criteria for proceeding to stage II. Although the URD arm met the criteria for stage II, the study was terminated owing to poor accrual and a significant number of failures. In all 19 transplant recipients, ruxolitinib was tapered successfully without significant side effects, and 9 patients (47%) had a significant decrease in symptom burden. The cumulative incidences of GF, NRM, acute graft-versus-host disease (GVHD), and chronic GVHD at 24 months were 16%, 28%, 64%, and 76%, respectively. On an intention-to-treat basis, the 2-year overall survival was 61% for the RD arm and 70% for the URD arm. Ruxolitinib can be integrated as pretransplantation treatment for patients with MF, and a tapering strategy before transplantation is safe, allowing patients to commence conditioning therapy with a reduced symptom burden. However, GF and NRM remain significant. |
| spellingShingle | Gupta, V Kosiorek, H Mead, A Klisovic, R Galvin, J Berenzon, D Yacoub, A Viswabandya, A Mesa, R Goldberg, J Price, L Salama, M Weinberg, R Rampal, R Farnoud, N Dueck, A Mascarenhas, J Hoffman, R Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 study |
| title | Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 study |
| title_full | Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 study |
| title_fullStr | Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 study |
| title_full_unstemmed | Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 study |
| title_short | Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 study |
| title_sort | ruxolitinib therapy followed by reduced intensity conditioning for hematopoietic cell transplantation for myelofibrosis myeloproliferative disorders research consortium 114 study |
| work_keys_str_mv | AT guptav ruxolitinibtherapyfollowedbyreducedintensityconditioningforhematopoieticcelltransplantationformyelofibrosismyeloproliferativedisordersresearchconsortium114study AT kosiorekh ruxolitinibtherapyfollowedbyreducedintensityconditioningforhematopoieticcelltransplantationformyelofibrosismyeloproliferativedisordersresearchconsortium114study AT meada ruxolitinibtherapyfollowedbyreducedintensityconditioningforhematopoieticcelltransplantationformyelofibrosismyeloproliferativedisordersresearchconsortium114study AT klisovicr ruxolitinibtherapyfollowedbyreducedintensityconditioningforhematopoieticcelltransplantationformyelofibrosismyeloproliferativedisordersresearchconsortium114study AT galvinj ruxolitinibtherapyfollowedbyreducedintensityconditioningforhematopoieticcelltransplantationformyelofibrosismyeloproliferativedisordersresearchconsortium114study AT berenzond ruxolitinibtherapyfollowedbyreducedintensityconditioningforhematopoieticcelltransplantationformyelofibrosismyeloproliferativedisordersresearchconsortium114study AT yacouba ruxolitinibtherapyfollowedbyreducedintensityconditioningforhematopoieticcelltransplantationformyelofibrosismyeloproliferativedisordersresearchconsortium114study AT viswabandyaa ruxolitinibtherapyfollowedbyreducedintensityconditioningforhematopoieticcelltransplantationformyelofibrosismyeloproliferativedisordersresearchconsortium114study AT mesar ruxolitinibtherapyfollowedbyreducedintensityconditioningforhematopoieticcelltransplantationformyelofibrosismyeloproliferativedisordersresearchconsortium114study AT goldbergj ruxolitinibtherapyfollowedbyreducedintensityconditioningforhematopoieticcelltransplantationformyelofibrosismyeloproliferativedisordersresearchconsortium114study AT pricel ruxolitinibtherapyfollowedbyreducedintensityconditioningforhematopoieticcelltransplantationformyelofibrosismyeloproliferativedisordersresearchconsortium114study AT salamam ruxolitinibtherapyfollowedbyreducedintensityconditioningforhematopoieticcelltransplantationformyelofibrosismyeloproliferativedisordersresearchconsortium114study AT weinbergr ruxolitinibtherapyfollowedbyreducedintensityconditioningforhematopoieticcelltransplantationformyelofibrosismyeloproliferativedisordersresearchconsortium114study AT rampalr ruxolitinibtherapyfollowedbyreducedintensityconditioningforhematopoieticcelltransplantationformyelofibrosismyeloproliferativedisordersresearchconsortium114study AT farnoudn ruxolitinibtherapyfollowedbyreducedintensityconditioningforhematopoieticcelltransplantationformyelofibrosismyeloproliferativedisordersresearchconsortium114study AT duecka ruxolitinibtherapyfollowedbyreducedintensityconditioningforhematopoieticcelltransplantationformyelofibrosismyeloproliferativedisordersresearchconsortium114study AT mascarenhasj ruxolitinibtherapyfollowedbyreducedintensityconditioningforhematopoieticcelltransplantationformyelofibrosismyeloproliferativedisordersresearchconsortium114study AT hoffmanr ruxolitinibtherapyfollowedbyreducedintensityconditioningforhematopoieticcelltransplantationformyelofibrosismyeloproliferativedisordersresearchconsortium114study |